Etrasimod
Indication
Treating moderately to severely active ulcerative colitis in people aged 16 and over (NICE TA956)
Red
Brand:
Velsipity
Nice TA:
956
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
1.1 Etrasimod is recommended, within its marketing authorisation, as an option for moderately to severely active ulcerative colitis in people aged 16 years and over when:
conventional or biological treatments cannot be tolerated or
the condition has not responded well enough, or lost response to treatment.
Etrasimod is only recommended if the company provides it according to the commercial arrangement.